78 TH SCIENTIFIC SESSIONS PRODUCT THEATER SCHEDULE SATURDAY, JUNE 23, 2018

Transcription

1 78 TH SCIENTIFIC SESSIONS PRODUCT THEATER SCHEDULE Product Theaters, located within the Exhibit Hall, offer informative sessions focusing on products or a single facet of diabetes. Product Theater sessions do not provide continuing education credit. These sessions are intended for health care professionals only with practices relevant to the presented information. Light refreshments provided by the ADA will be served to the first 300 attendees. SATURDAY, JUNE 23, 2018 Continuous Glucose Monitoring Reinvented Introducing the FreeStyle Libre System Presented by Abbott Introducing the FreeStyle Libre System. Simple accurate, 1 and more affordable* continuous glucose monitoring for your patients. 1. FreeStyle Libre User s Manual. * Based on the manufacturer s list price of the FreeStyle Libre system. The actual cost to you may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any. Presenters: W. Reid Litchfield, MD, FACE, ECNU, FRCP Desert Endocrinology Nevada Thyroid Institute Henderson, NV Special Guest Speaker Cardiovascular Disease Burden in the U.S. and Clinical Evaluation of VASCEPA (Icosapent Ethyl) Presented by Amarin Pharma, Inc. Hear from an expert about cardiovascular disease burden in the U.S. and clinical evaluation of VASCEPA (icosapent ethyl). Despite the benefits of LDL-C lowering, many patients on statin therapy remain at risk. In this presentation, new data and perspectives on the role of high triglycerides as a marker of increased cardiovascular risk in patients with statin-controlled LDL-C will be discussed. The clinical development program and safety for pure EPA VASCEPA will be reviewed. Eliot A. Brinton, MD President Utah Lipid Center Salt Lake City, UT

2 Introducing a New Era in Glucose Monitoring The Eversense Continuous Glucose Monitoring System Presented by Senseonics The world s first long-term implantable continuous glucose monitoring system. Based on novel fluorescence technology, Eversense provides continuous real-time readings up to 3 months with a single sensor. Get a first look at the product technology, which includes a wearable smart transmitter that can be taken on or off and provides discreet vibratory glucose alerts. Learn about the clinical performance resulting in sustained accuracy over the 3-month wear period. During this session, you will hear from clinicians and patients discussing firsthand experience with the technology. At the conclusion of the presentations, there will be a Q&A session. You don t want to miss this panel of industry experts and current Eversense users! Presenters: E. Lynne Kelley, MD, FACS Chief Medical Officer Senseonics, Inc Germantown, MD Timothy S. Bailey, MD, FACE, FACP, CPI President and CEO AMCR Institute, Inc. Escondido, CA Jenine Yager Stone, MSN, FNP-C Assistant Director, Clinical Research AMCR Institute, Inc. Escondido, CA 12:15 p.m.-1:15 p.m. Jardiance (Empagliflozin) Tablets Evolving Clinical Development Presented by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA This program will discuss recent data from the ongoing Jardiance clinical development program. The presentation will cover efficacy and safety data, as well as the dosing information for Jardiance. Attendees will also have the opportunity to ask the faculty questions about the data presented. Presenters: Leigh Perreault, MD Associate Professor of Medicine Division of Endocrinology, Metabolism, and Diabetes Affiliate Center for Global Health University of Colorado Anschutz Medical Campus Associate Professor of Epidemiology Colorado School of Public Health Boulder, CO Pam R. Taub, MD, FACC Associate Professor of Medicine University of California, San Diego Health System San Diego, CA

3 12:15 p.m.-1:15 p.m. The Role of GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Management Presented by AstraZeneca Pharmaceuticals This presentation will review the important role of glucagon-like peptide-1 (GLP-1) in physiologic glucose regulation and the mechanism of GLP-1 receptor agonists in addressing the core defects of type 2 diabetes. The clinical efficacy, safety, and potential place in therapy of a once-weekly, GLP-1 receptor agonist, prefilled autoinjector will be discussed. In addition, there will be a live demonstration of the autoinjector. Robert S. Busch, MD Albany Medical College Albany, NY 12:15 p.m.-1:15 p.m. Developments in GLP-1 Treatment Options for Adults with Type 2 Diabetes Presented by Novo Nordisk A/S James R. Gavin III, MD, PhD Clinical Professor of Medicine Emory University School of Medicine Chief Medical Officer Healing Our Village, Inc. Atlanta, GA 2:45 p.m.-3:30 p.m. Evaluating the Impact of a Safety Outcomes Trial Incidence of Major Adverse Cardiovascular Events and Clinical Importance of Severe Hypoglycemia for Type 2 Diabetes Patients Requiring a Long-Acting Insulin Presented by Novo Nordisk A/S Helena W. Rodbard, MD, FACP, MACE Medical Director Endocrine and Metabolic Consultants Rockville, MD

4 2:45 p.m.-3:30 p.m. Introducing the New Dexcom G6 Simple, Accurate, Effective Presented by Dexcom Introduction and Review of the new Dexcom G6 Continuous Glucose Monitoring System. Dexcom G6 CGM technology, features, accuracy, usability and product enhancement. Dexcom G6 pivotal trial data, patient experience, and training best practices. Presenters: Jake Leach Senior Vice President, Research and Development Dexcom San Diego, CA Keri Leone, MS, RD, CDE Senior Director, Global Professional Education Dexcom San Diego, CA R. Paul Wadwa, MD Associate Professor of Pediatrics University of Colorado School of Medicine Director of Telemedicine Medical Director, Pediatric Clinic, Barbara Davis Center for Childhood Diabetes Aurora, CO CT THEATERS

5 SUNDAY, JUNE 24, 2018 Praluent (Alirocumab) Injection The Time to Treat Is Now Presented by Sanofi-Regeneron Kenneth Feingold, MD Professor of Medicine University of California, San Francisco San Francisco, CA Criticality of LDL-C Lowering in Patients with Diabetes Mellitus Presented by Amgen Paul S. Jellinger, MD, MACE Professor of Clinical Medicine University of Miami Miller School of Medicine The Center for Diabetes and Endocrine Care Ft. Lauderdale, FL The Guardian Connect Continuous Glucose Monitoring System Utilizing Predictive Alerts and Data Backed Insights to Help with Diabetes Management Presented by Medtronic Please join us and learn how predictive alerts and data backed insights of the Guardian Connect Smart CGM system can help you and your patients with diabetes management. Presentation will include a system overview, real-world data, case studies, and best practices. Presenters: Timothy S. Bailey, MD, FACE, CPI President & CEO, AMCR Institute, Inc. Clinical Associate Professor of Medicine University of California, San Diego Escondido, CA Huzefa Neemuchwala, PhD, MBA Senior Director, Data and Digital Information Medtronic Diabetes Northridge, CA

6 12:30 p.m.-1:30 p.m. Pneumococcal Disease in Adults Aged <65 Years with Diabetes or Other Select Chronic Conditions Presented by Merck & Co., Inc. Describe pneumococcal disease in adults aged <65 years with diabetes or other select chronic conditions. Review CDC recommendations for pneumococcal vaccination in this population. PNEUMOVAX 23 pneumococcal disease vaccine (pneumonia, meningitis, bacteremia). PRODUCT THEATERS 12:20 p.m.-1:30 p.m. Improving Glycemic Control in Type 1 Diabetes The Role of Insulin-Independent Pathways Presented by Lexicon Pharmaceuticals and Sanofi Yehuda Handelsman, MD, FACP, FNLA, MACE Medical Director & Principal Investigator Metabolic Institute of America Tarzana, CA 12:30 p.m.-1:30 p.m. Severe Hypertriglyceridemia and Pancreatitis Including Familial Chylomicronemia Syndrome (FCS) in Your Differential Diagnosis Presented by Akcea Therapeutics This program provides clinicians with information on Familial Chylomicronemia Syndrome (FCS), a disease in which inherited defects result in the accumulation of chylomicrons in the plasma causing acute pancreatitis and sequelae which can impact daily life including recurrent pain, recurrent acute pancreatitis, and permanent pancreatic damage. Is a patient like this in your practice? Severe, refractory hypertriglyceridemia o TG>880 mg/dl o Not responsive to standard triglyceride-lowering therapies No secondary causes of hypertriglyceridemia One or more of: o History of pancreatitis o History of recurrent abdominal pain without other explainable cause Objectives for attending clinicians include: Differentiate the FCS patient from patients with secondary causes of hypertriglyceridemia Appreciate the importance of FCS diagnosis Understand the value of connecting FCS patients to educational resources and the FCS patient community Richard L. Dunbar, MD Perelman School of Medicine University of Pennsylvania Philadelphia, PA

7 3:00 p.m.-3:45 p.m. Basal Insulin Treatment Considerations in Adult Patients with Type 2 Diabetes Mellitus Presented by Sanofi Carol H. Wysham, MD Clinical Professor of Medicine University of Washington Spokane, WA 3:00 p.m.-3:45 p.m. Closing the Loop with Blood Glucose Meters Supporting Current Continuous Glucose Monitoring and Future Therapies Presented by Ascensia Diabetes Care As diabetes management solutions continue to evolve, for all people with diabetes, the use of Blood Glucose Meters (BGM) play an integral role in supporting other technologies such as Continuous Glucose Monitors (CGM), Flash Glucose Monitors (FGM), Hybrid Closed-Loop System (HCLS) (such as the Medtronic MiniMed 670G), and Artificial Pancreas Device Systems (APDS). This session will discuss these technologies and the role of BGM within each. Steven Edelman, MD Division of Endocrinology and Metabolism University of California, San Diego Founder/Director Taking Care Of Your Diabetes (TCOYD) San Diego, CA PRODUCT THEATERS

8 MONDAY, JUNE 25, 2018 MiniMed 670G System Increasing Time In Range with Automated Insulin Delivery Presented by Medtronic Please join us and learn how the MiniMed 670G system has changed the way we are managing time in range for patients with type 1 diabetes. Presentation will include real-world data, case studies, and best practices. Presenters: Jennifer Sherr, MD, PhD Pediatric Endocrinologist, Associate Professor Yale School of Medicine New Haven, CT Anders L. Carlson, MD Medical Director International Diabetes Center at Park Nicollet Minneapolis, MN Repatha (Evolocumab) Putting It into Practice Presented by Amgen Join Eliot A. Brinton, MD, FAHA, FNLA, as he conducts an educational presentation on the importance of Repatha (evolocumab). Hear about his experience with Repatha and the options available for appropriate patients. Eliot A. Brinton, MD, FAHA, FNLA President Utah Lipid Center Salt Lake City, UT DCT THEATERS 12:30 p.m.-1:30 p.m. The Omnipod DASH System Simplifying Insulin Delivery for Your Patients and Practice Presented by Insulet Corporation Learn how the Omnipod DASH Insulin Management System will build on the simplicity and ease-ofuse of the existing Omnipod System platform leveraging its tubeless, waterproof design to address the needs of people with insulin-dependent diabetes. The Omnipod DASH System includes the Pod that will remain unchanged in size with Bluetooth technology for greater connectivity to the Personal Diabetes Manager (PDM) as well as to the compatible Contour NEXT One Blood Glucose (BG) Meter. The new, slimmer PDM will feature a color touchscreen interface and will enable discreet insulin delivery with a few finger taps. A new suite of ios mobile applications will give users and their caregivers quick and easy access to their insulin therapy information on their smartphones. The Omnipod DASH system will also be compatible with Insulet Provided Glooko for easy data upload, improved care team collaboration, and access to meaningful data context which will allow for informed diabetes management decisions. Come to our Product Theater to learn more about the Omnipod DASH System and Insulet s commitment to reducing the burden of diabetes for health care providers, users, and their caregivers. Caution: Pending 510(k) clearance. Not available for sale in the U.S.

9 Presenters: Trang Ly, MBBS, FRACP, PhD Senior Vice President and Medical Director Insulet Corporation Billerica, MA Daniel DeSalvo, MD Assistant Professor of Pediatrics of Diabetes & Endocrinology Baylor College of Medicine/Texas Children s Hospital Houston, TX 12:30 p.m.-1:30 p.m. A Treatment Option for Adults with Type 2 Diabetes Presented by Merck & Co., Inc. Review select prescribing information for a type 2 diabetes therapeutic option. Lance Sloan, MD, FACE, FASN Private Practice Lufkin, TX